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Treatment response in schizophrenia divides into three subcategories: treatment-responsive (first-
line responders; FLR), treatment-resistant (TRS), and ultra-treatment-resistant schizophrenia (UTRS). 
White matter abnormalities could drive antipsychotic resistance but little work has investigated 
differences between TRS and UTRS. The current study aimed to establish whether differences in 
white matter structure are present across both treatment-resistant subtypes or if UTRS is distinct 
from TRS. Diffusion-weighted images were acquired for 18 individuals with TRS, 14 with UTRS, 18 
FLR and 20 healthy controls. Measures of fractional anisotropy (FA), mean diffusivity (MD), radial 
diffusivity (RD) and axial diffusivity (AD) were obtained using tract-based spatial statistics. Analysis of 
variance and post-hoc t-tests were conducted for each measure. Those with TRS had lower FA than 
healthy controls in superior longitudinal fasciculus, corpus callosum, thalamic radiation, corticospinal 
tract, internal capsule, corona radiata and fronto-occipital fasciculus (p<.05 FWE-corrected). Lower 
FA was also observed in TRS compared with UTRS in the superior longitudinal fasciculus (p<.05 FWE-
corrected). No post-hoc tests survived corrections for multiple comparisons and no differences in 
MD, AD or RD were observed. These data suggest that microstructural deficits in white matter could 
contribute to TRS but suggest that other mechanisms may be more relevant for UTRS.  
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Pharmacological intervention is the most effective treatment for schizophrenia (Matheson et al., 
2014). However, the rate of response to initial treatment with typical or atypical non-clozapine 
antipsychotics reaches only 60% to 80%, with response rates to a second non-clozapine 
antipsychotic as low as 16% (Agid et al., 2011; Elkis and Buckley, 2016). Resistance to first-line 
antipsychotic therapy accounts for some of the highest rates of hospitalisation and impaired 
functioning in mental health (Iasevoli et al., 2016; Lieberman and Murray, 2012) and is estimated to 
require USD 34 billion per annum in direct healthcare costs in the US alone (Kennedy et al., 2014). 
Furthermore, a recent meta-analysis (Siskind et al., 2017) revealed that clozapine, the most effective 
treatment for first-line therapy-resistant schizophrenia, is effective in only 40% of treatment-
refractory individuals, suggesting that 12% to 20% of people with schizophrenia are ultra-treatment-
resistant. Reflecting on these observations, researchers have posited that these three response 
levels represent three distinct subtypes of schizophrenia: treatment-responsive (first-line 
responders; FLR), treatment-resistant (clozapine responders; TRS) and ultra-treatment-resistant 
schizophrenia (clozapine-resistant; UTRS) (Farooq et al., 2013; Lee et al., 2015).  
A growing body of research investigating potential differences in structural brain organisation 
between response subtypes of schizophrenia lends support to the concept of treatment-based 
categorical distinctions in this disorder and suggests that differences in white matter structure are 
present even at first episode of psychosis (Chen et al., 2018; Reis Marques et al., 2014). Reis 
Marques et al. (2014) reported that, at baseline, individuals with first-episode psychosis who failed 
to respond to a 12-week course of first-line antipsychotic therapy had lower fractional anisotropy 
(FA) than either healthy comparison subjects or responders in the left uncinate fasciculus, cingulum 
and superior longitudinal fasciculus and commissural tracts such as the corpus callosum (responders 
were indistinguishable from healthy comparison subjects). In support of these findings, Chen et al. 
(2018) identified white matter impairments in the right temporal and occipital lobes in resistant 
compared with responsive individuals with first-episode psychosis following one year of 
antipsychotic treatment. Differences in FA between responders and non-responders to first-line 
therapy also appear to persist throughout the course of disease. Widespread reductions in FA have 
been reported in patients who met criteria for TRS prior to commencing clozapine when compared 
to healthy subjects (Holleran et al., 2013), as well as in those with TRS with severe symptoms 
compared with non-treatment resistant schizophrenia (Ochi et al., 2020). Researchers also identified 
lower FA in the body of the corpus callosum in those with clozapine-eligible schizophrenia compared 
with FLR (McNabb et al., 2018a), as well as reduced mean generalised FA within 12 white matter 
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tracts in people with non-remitting compared with remitting schizophrenia (Huang et al., 2018). Two 
earlier cross-sectional studies of patients with chronic schizophrenia also reported that a poor 
response to antipsychotic treatment was associated with lower FA in the whole brain and in specific 
tracts such as the uncinate and superior longitudinal fasciculi (Luck et al., 2011; Mitelman et al., 
2006).  
Although these studies provide mounting evidence for a role of white matter aberrations in 
treatment-resistant subtypes of schizophrenia, they have focused primarily on comparisons with 
healthy controls and differences between FLR and those with TRS (or poor treatment outcome), 
either omitting those with UTRS or absorbing them into the TRS subtype. If a diagnosis of 
schizophrenia really does divide into three distinct response subtypes, studies should be designed to 
distinguish between FLR, individuals with TRS and those with UTRS. Therefore, the current study 
sought to investigate white matter markers of treatment response in people with schizophrenia 
using the classification scheme proposed by Farooq et al. (2013) and Lee et al. (2015); specifically 




Details of participant recruitment have been described previously (Anderson et al., 2015; Goldstein 
et al., 2015; McNabb et al., 2018b). Individuals with a diagnosis of schizophrenia according to the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) were recruited from mental health 
services (a community mental health centre or forensic psychiatric inpatient unit) in Auckland, New 
Zealand. Participants were enrolled into one of three study arms (FLR, TRS or UTRS). Those who 
were responding well to first-line atypical antipsychotic monotherapy were assigned to the FLR 
group; response was defined as an improvement of positive symptoms according to standard 
practice and current treatment guidelines for schizophrenia (Lehman et al., 2004; McGorry, 2005). 
Those who had failed at least two previous six-to-eight-week trials of atypical antipsychotics and 
were receiving clozapine at the time of screening were assigned to the TRS group and participants 
who had failed at least two previous six-to-eight-week trials of atypical antipsychotics and had also 
failed an adequate trial of clozapine monotherapy (at least 8 weeks post titration (Mouaffak et al., 
2006)) were assigned to the UTRS group. Participants in TRS and UTRS groups met minimum 
requirements for diagnosis of TRS or UTRS, respectively, according to Treatment Response and 
Resistance in Psychosis (TRRIP) working group guidelines (Howes et al., 2016). All participants’ 
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clinical records were inspected by a registered pharmacist (MM) to ensure they had received 
adequate trials of antipsychotics at appropriate dosages for an appropriate length of time and to 
ensure that those in the UTRS cohort had been switched from clozapine monotherapy due to poor 
treatment response rather than poor adherence or clozapine-induced side effects. Patients in all 
treatment groups were required to be at most mildly ill, determined using the Clinical Global 
Impression (CGI) (which corresponds to a score of 3 out of 7 using this scale; 7 being the most 
extremely ill) to control for state effects (as otherwise differences in the TRS/UTRS groups could be 
ascribed to the presence of more severe symptoms). A healthy comparison group with no history of 
mental or neurological illness was recruited by advertising in the community. Age, sex and ethnicity 
were matched on a group basis. All participants were between the ages of 18 and 45 years. Exclusion 
criteria were as follows: history of traumatic brain injury (loss of consciousness for more than three 
minutes), neurological illness, significant physiological comorbidity or contraindication to magnetic 
resonance imaging (MRI). The study was approved by the Northern X Regional Ethics Committee 
(reference: NTX/09/05/042) and conducted in accordance with the Helsinki Declaration as revised in 
1989. All participants gave informed written consent - ability to give informed consent was judged 
by the treating psychiatrist. 
Duration of psychosis and Positive and Negative Syndrome Scale (PANSS) scores (Kay et al., 1987) 
were assessed at study entry by a study investigator (MM) who had received professional PANSS 
training (including use of consensus videos) by a registered psychiatrist. Antipsychotic dose at the 
time of assessment was converted to chlorpromazine equivalents (CPZE) using formulae with power 
transformation (Andreasen et al., 2010). In the absence of a power formula for amisulpride, CPZE 
were calculated using expert consensus regarding antipsychotic dosing (Gardner et al., 2010). Past 
and present substance abuse was evaluated using the Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST; World Health Organisation) at study entry. Participants also provided a urine 
sample, which was screened for the presence of amphetamine, methamphetamine, 
benzodiazepines, cocaine, opiates and tetrahydrocannabinol (THC) (Medix Pro-Split Integrated Cup, 
Multi Drug Screening Test; Sobercheck Ltd). Standardised premorbid intelligence quotient (IQ) 
scores were determined using a computerised version of the “spot the real word” task within the 
IntegNeuro test battery (Brain Resource Company, Sydney, Australia) (Baddeley et al., 1993; Gordon, 
2003; Gordon et al., 2005). The sample size was based on previous studies examining the 
relationship between treatment outcomes and diffusion tensor imaging (DTI) measures in 
schizophrenia (Garver et al., 2008; Luck et al., 2011; Mitelman et al., 2009) and compares with more 
recent studies investigating white matter microstructure in individuals with treatment-resistant 
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schizophrenia (e.g. 20 FLR + 20 TRS (Chen et al., 2018), 27 Controls + 28 FLR + 24 TRS (Ochi et al., 
2020)).  
2.2. Image acquisition and pre-processing 
Scanning was performed using a 3T Siemens Magnetom Skyra (Siemens, Germany). A 32-channel 
head coil was used for the majority of scans; where the participant could not fit comfortably into this 
coil, a 20-channel head coil was used (FLR = 2, TRS = 1, UTRS = 2; see Supplementary Materials for 
further details). T1-weighted images were acquired using a magnetization-prepared 180-degrees 
radio-frequency pulses and rapid gradient-echo (MPRAGE) sequence (Brant-Zawadzki et al., 1992). 
Acquisition parameters were as follows: repetition time (TR) 1900 ms; echo time (TE) 2.39 ms; 
inversion time (TI) 900 ms; flip angle 9°; repetition 1; acceleration factor 2; field of view (FOV) 230 
mm; matrix 256 x 256; voxel size 0.9 x 0.9 x 0.8 mm. Diffusion-weighted images were acquired using 
an echo planar imaging (EPI) sequence with the following parameters: phase encoding A>>P, TR 
8900 ms, TE 95 ms, FOV 240 mm, matrix 122 x 122, 2.0 mm slice thickness, isotropic voxel size 2.0 x 
2.0 x 2.0 mm. An acceleration factor (GRAPPA) of 2 was used. Sixty-seven slices were acquired in the 
anterior to posterior direction with diffusion-weighting factor b=1000s/mm2 in 64 unique gradient-
encoding directions. Eight scans without diffusion weighting (b=0) were also acquired. All scans were 
visually examined for artefacts including subject motion, excess signal-to-noise and incomplete 
acquisitions. No participants were excluded on this basis. 
Image preprocessing and analysis were performed using the FMRIB Software Library (FSL) (Jenkinson 
et al., 2012). Raw diffusion-weighted images were corrected for head motion and eddy current 
distortions using FSL’s eddy tool (Andersson and Sotiropoulos, 2016). In-scanner head motion from 
the first volume and the previous volume were determined and averaged across volumes to give two 
root mean squared values for each participant. Susceptibility-induced distortions were corrected 
using FSL’s fugue function and output registered to gradient-free images using the linear registration 
function (FLIRT) (Jenkinson et al., 2002). 
Measures of white matter microstructure, including FA, mean diffusivity (MD), axial diffusivity (AD) 
and radial diffusivity (RD) were obtained using Tract-Based Spatial Statistics (TBSS) (Smith et al., 
2006), part of FSL (Smith et al., 2004). FA images were created by fitting a tensor model to the raw 
diffusion data using FMRIBs Diffusion Toolbox (FDT), and then brain-extracted using the Brain 
Extraction Tool (BET) (Smith, 2002). All subjects' FA data were then aligned to the FMRIB58_FA 
target image using the nonlinear registration tool FNIRT (Andersson et al., 2007) which uses a b-
spline representation of the registration warp field (Rueckert et al., 1999) and transformed into 
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Montreal Neurologic Institute (MNI)-152 standard space. Next, a mean FA skeleton representing the 
centres of all white matter tracts common to the group was created and thinned at a threshold of 
0.3 to exclude low anisotropic regions. Each subject's aligned FA data were then projected onto this 
skeleton. Anatomical localisation of significant white matter clusters was determined using the 
Juelich histological white matter labels and tractography atlases. The same approach was used for 
preprocessing of MD, AD and RD data. 
2.3. Statistical analysis 
Whole-brain statistical analyses were performed using FSL’s Randomise tool. Threshold-free cluster 
enhancement was used for statistical comparisons, utilising a nonparametric permutation test in 
which group membership was permuted 5,000 times to generate a null distribution for each 
contrast. An analysis of variance (ANOVA) was employed to investigate whether any difference 
between groups existed in the data. Post hoc unpaired t-tests were then used to explore potential 
differences between the groups. Age and sex were demeaned prior to analysis and included as 
covariates of no interest in both ANOVA and post hoc analyses (Bose et al., 2009). Additional 
regression correlations (Pearson) were performed to investigate the associations between white 
matter measures and participant head motion, as well as daily antipsychotic dose in CPZE. All voxel-
wise p-values were corrected for multiple comparisons using a Family-Wise Error (FWE) correction 
threshold of p = .05; post hoc tests were corrected for multiple comparisons using the False 
Discovery Rate (FDR). Both corrected and uncorrected post hoc t-test results are reported.  
Head motion during scanning can introduce bias that may influence microstructural measures of 
white matter (Ling et al., 2012). To evaluate the effect of motion on FA, we conducted a regression 
analysis between FA and root mean squared motion from first and previous volumes.  
Analyses of socio-demographic and clinical characteristics were conducted using the Psych and 
DescTools packages for R (R Core Development Team, 2012; Revelle, 2017; Signorell et al., 2019). 
ANOVA was used to compare continuous variables with Bonferroni correction for multiple 
comparisons of post hoc tests. Fisher’s Exact test was used for comparisons of non-parametric data. 







A total of 70 participants (20 healthy controls, 18 FLR, 18 individuals with TRS and 14 with UTRS) 
were included in the final analysis. Demographic and clinical data are summarized in Table 1. There 
were no significant differences in gender, age, IQ or positive tests for THC between the groups, 
though ASSIST scores were higher in FLR and those with UTRS compared with healthy controls. No 
differences in duration of illness, duration of untreated psychosis, PANSS total scores, or any of the 
subscales were observed between the groups with schizophrenia. Those with UTRS were receiving a 
higher dose of antipsychotics (measured in CPZE) at the time of scanning compared with both FLR 
and those with TRS; clusters demonstrating differences in FA between treatment groups were 
therefore correlated against CPZE to determine whether antipsychotic dose affected the results. The 
same was done for ASSIST scores and cluster FA. 
Root mean squared motion from the first volume and the previous volume were evaluated for each 
participant. No statistically significant differences in motion were identified between treatment 
groups (see Table 1).  
3.2. TBSS results 
An ANOVA between all study groups revealed a statistically significant effect for FA (p = .048), 
indicating an effect of group on white matter microstructure. No such effect was observed for MD, 
AD or RD. Pairwise comparisons between groups (FWE-corrected) revealed lower FA in those with 
TRS compared to healthy controls (figure 1; p = .022 uncorrected) as well as those with UTRS (figure 
2; p = .030 uncorrected). Neither test survived corrections for multiple post hoc comparisons 
between groups using the FDR; however, the consistency of our findings with the literature to date 
suggests that this is most likely a result of small sample size as opposed to false positive results.   
Clusters with lower FA in those with TRS are shown in figure 3 and described further in table 2. 
Those with TRS had lower FA than controls in the superior longitudinal fasciculus (bilateral), corpus 
callosum, thalamic radiation (bilateral), corticospinal tract (bilateral), internal capsule (left), corona 
radiata (bilateral) and fronto-occipital fasciculus (bilateral), among other regions. In contrast, 
differences between those with TRS and UTRS were confined to the right superior longitudinal 
fasciculus (including the temporal component of the superior longitudinal fasciculus). 
To further interrogate the differences between groups, mean FA for each cluster was determined for 
every participant (figure 4). FA was lowest in those with TRS for all clusters and, for the most part, 
was similar for FLR and those with UTRS, both of which had slightly lower FA than healthy controls. 
The exception was for the single cluster exhibiting lower FA in those with TRS compared with UTRS, 
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in which the effect appears to be driven by a combination of low FA in those with TRS and high FA in 
those with UTRS. 
3.3. Correlation with clinical characteristics 
As CPZE demonstrated differences between treatment groups, we ran additional regression analyses 
investigating the relationships between CPZE and white matter measures. There was no area 
identified where FA, MD, AD or RD correlated with antipsychotic daily dose in CPZEs. Likewise, no 
statistically significant relationship between cluster FA and antipsychotic dose measured in CPZE was 
identified when measured independently for each cluster (figure 5). Similar analyses were conducted 
for PANSS total score and age at onset of psychosis in those with schizophrenia and no significant 
relationships to cluster FA values were identified (see supplementary figures S1 and S2, 
respectively).  
3.4. Correlation with socio-demographic characteristics 
As previous work found significant associations between IQ and FA (Luders et al., 2007; Luders et al., 
2011; Navas‐Sánchez et al., 2014), for each cluster, we ran correlations between mean FA and 
standardised (premorbid) IQ. IQ correlated with mean FA in two clusters (figure 6), although only 
one survived corrections for multiple comparisons across clusters (Bonferroni-corrected p threshold 
.007). The significant correlation was for a cluster spanning only 5 voxels (located in the left external 
capsule / inferior fronto-occipital fasciculus / uncinate fasciculus) whereby those with TRS had lower 
FA than healthy controls. The remaining clusters showed no relationship between FA and IQ.  
Recreational drug-use (measured using the ASSIST) was higher in FLR and those with UTRS compared 
with controls. In addition, as lifetime drug use, in particular use of THC (Epstein and Kumra, 2015), 
may influence white matter microstructure in tracts relevant to schizophrenia, we ran Pearson’s 
correlations between ASSIST scores and FA values in each cluster. One participant failed to complete 
the ASSIST and was excluded from the analysis. Results are presented in figure S3. No statistically 
significant relationship between ASSIST score and cluster FA was identified for any cluster.  
3.5. Effect of head motion on FA 
Root mean squared motion did not significantly correlate with FA in the regression analysis. 
However, adding motion values as regressors of no interest in the main ANOVA resulted in a loss of 




Results from studies investigating white matter microstructure in people with schizophrenia have 
contributed toward a consensus that people who fail to respond to first-line antipsychotic therapy 
exhibit greater disruptions in FA than treatment responders (Chen et al., 2018; Huang et al., 2018; 
McNabb et al., 2018a; Ochi et al., 2020; Reis Marques et al., 2014). However, schizophrenia 
encompasses two distinct subtypes of treatment resistance  ̶  clozapine responsive treatment 
resistance (TRS) and clozapine resistant treatment resistance (UTRS). This was the first study to 
explicitly define and compare these two subtypes in addition to FLR and healthy controls to 
investigate possible white matter markers of treatment resistance in people with schizophrenia. 
Importantly, treatment resistance in the current study was evaluated on the basis of past treatment 
failure in addition to current treatment response (i.e. did the person respond to treatment with 
clozapine monotherapy?) - Therefore, TRS and UTRS groups should be interpreted as clozapine 
monotherapy-responsive and clozapine monotherapy-resistant, respectively, rather than exhibiting 
increasing degrees of symptom severity. 
Our results suggest that TRS and UTRS are likely distinct from one another in their white matter 
profiles, TRS exhibiting lower FA than both healthy controls and UTRS. Therefore, resistance to the 
clinical benefits of first-line antipsychotic drugs and subsequent sensitivity to clozapine may be 
attributable to global disruptions in FA. By comparison, those with UTRS had FA comparable to FLR 
and healthy controls, suggesting that white matter disruptions play a less pivotal role in treatment 
resistance for these individuals. A caveat of the current research is that head motion (although not 
significantly different between groups, see Table 1) was higher in healthy controls than those with 
TRS. Adding head motion as a regressor in the analysis led to a non-significant effect of group. With 
limited sample size, this loss of significant effect may be attributable to a loss in degrees of freedom, 
but could reflect real differences in motion between groups contributing to the overall group effect 
on FA in the main analysis. We therefore caution that these results be interpreted with care, though 
their resemblance to previous findings (Chen et al., 2018; Huang et al., 2018; Luck et al., 2011; 
Mitelman et al., 2006; Ochi et al., 2020; Reis Marques et al., 2014) suggests that they do make a 
valuable contribution to the literature.  
Prominent regions of white matter disruptions in our TRS cohort included the superior longitudinal 
fasciculus (including the temporal region of this tract), body and splenium of the corpus callosum 
and forceps major, corticospinal tract, superior and posterior corona radiata, posterior limb of the 
internal capsule, anterior and posterior thalamic radiation, the external capsule, uncinate fasciculus, 
inferior fronto-occipital fasciculus and cerebral peduncle. Our findings of widespread white matter 
aberrations in those with TRS are in agreement with previous studies investigating white matter 
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microstructure in responders and non-responders to first-line therapy. Luck et al. (2011) identified 
reduced FA in people with chronic schizophrenia experiencing poor response compared with healthy 
controls within the superior longitudinal fasciculus and uncinate fasciculus but not the cingulum, 
with FA reductions more pronounced in the poor outcome compared with good outcome group 
(Luck et al., 2011). Likewise, Reis Marques et al. (2014) found that those who went on to develop a 
poor response to antipsychotic treatment exhibited decreased FA across multiple white matter 
regions, including the left uncinate, cingulum and superior longitudinal fasciculus and corpus 
callosum, compared to healthy controls. The corpus callosum is the fundamental white matter 
structure conferring interhemispheric connectivity. Lower FA in the forceps major, splenium and 
body of the corpus callosum in our TRS group is in agreement with previous studies investigating 
treatment resistance, as well as schizophrenia more generally. Decreased FA in the corpus callosum 
is consistently reported in patients with schizophrenia (Bora et al., 2011; Foong et al., 2000; Kong et 
al., 2011; Kubicki et al., 2008; Patel et al., 2011) and more specifically chronic schizophrenia (Douaud 
et al., 2007; Koch et al., 2010; Kubicki et al., 2008; Mitelman et al., 2009; Miyata et al., 2010; 
Rotarska-Jagiela et al., 2008). Mitelman et al. observed lower average FA in the corpus callosum of 
individuals with schizophrenia with poor-outcome compared with good outcome (Mitelman et al., 
2009). Lower FA in the body of the corpus callosum has also been observed in people with 
schizophrenia who are eligible for clozapine compared with those responding well to first-line 
antipsychotic therapy (McNabb et al., 2018a). Though we did not detect differences between FLR 
and TRS patient groups in the current study, FA was lowest in the group with TRS throughout the 
corpus callosum body, splenium and forceps major, suggesting that callosal aberrations are most 
severe in this population. 
Our finding of lower FA in the fronto-occipital fasciculus may be driven by disruptions in myelination 
in those with TRS. A recent study investigating magnetic resonance markers of myelination found 
lower myelin water fraction in people with schizophrenia compared with healthy controls in this 
region, although no difference between resistant and responsive patients were observed (Vanes et 
al., 2018). Myelin water fraction within the corpus callosum was also associated with cognitive 
control in those with schizophrenia. In their study, Vanes et al. (2018) explicitly excluded individuals 
receiving clozapine to avoid the introduction of subgroups including ultra-treatment-resistant 
schizophrenia. However, we have demonstrated that this subgroup exhibits white matter patterns 
quite distinct from TRS, suggesting that distinguishing TRS from UTRS provides useful information 
about the treatment response patterns of individuals with schizophrenia.  
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Although we did not demonstrate significant differences in white matter between all schizophrenia 
cohorts and healthy controls in the current analysis, a previous analysis of the same participants 
identified lower white matter volume in all schizophrenia groups compared with controls (Anderson 
et al., 2015). Therefore, the lower (but not statistically significant) FA observed in FLR (and to a lesser 
extent those with UTRS) compared with healthy controls could indicate a less severe but still 
clinically relevant reduction in FA in these individuals.  
Differences in FA between controls and TRS as well as between those with TRS and UTRS appear to 
be strongly lateralised in the current study. However, increasing the statistical threshold to include 
“trend-level” (p≤.1) differences in FA revealed a more bilateral pattern of FA deficits in those with 
TRS (data not shown). As statistically significant clusters identified in the current analysis had p-
values close to the threshold value of p=.05, the lateralisation observed here may be a feature of the 
statistical cut-off rather than indicating true lateralised disruption in white matter microstructure. 
Further studies in larger samples will be necessary to determine whether any biologically meaningful 
conclusions can be made from this supposed lateralisation.   
All participants in the TRS group and the majority of participants in the UTRS groups were receiving 
clozapine at the time of scanning. Previous studies have associated both a reduction in white matter 
volume (Molina et al., 2005) and increase in FA (Ozcelik-Eroglu et al., 2014) with the use of 
clozapine. As our results demonstrate lower FA in those on clozapine monotherapy and similar levels 
of FA in those with UTRS (receiving augmented clozapine therapy) and FLR, it is unlikely that our 
effects are driven by exposure to clozapine. However, if FA is lowest in those with TRS and clozapine 
increases FA, this could be a mechanism by which clozapine improves symptoms of the disorder. 
Current antipsychotic dose is also unlikely to have driven the effects observed in this study. As the 
UTRS group were receiving significantly higher doses of antipsychotics (measured in CPZE) compared 
with both FLR and those with TRS, we ran correlations within the whole brain and significant FA 
clusters to determine the effects of CPZE. No significant effects were observed in either analysis, 
suggesting that the lower FA in those with TRS is independent of antipsychotic exposure. Although 
no effect of current dosage was found, as it was not possible to obtain cumulative lifetime exposure 
to antipsychotics (due to limited information available in public health records), we cannot rule out 
the potential for more long-term effects of antipsychotic dosage to have impacted FA. Likewise, 
family history of psychiatric symptoms was not accounted for in the current study but may have had 
some influence on our findings. 
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Although past and present recreational drug use was higher in FLR and those with UTRS compared 
with healthy controls, no relationship between ASSIST scores and FA were identified for any cluster. 
These results suggest that the lower FA identified in those with TRS compared with controls and 
those with UTRS is unlikely to be driven by the effects of recreational drug use on white matter 
microstructure. 
We did, however, identify a relationship between IQ and mean FA in one of the seven clusters 
(located in the external capsule) demonstrating differences between TRS and healthy controls. IQ 
has been shown to correlate with white matter microstructure in the external capsule in previous 
research (Navas‐Sánchez et al., 2014); however, as the cluster demonstrating a significant effect 
contained only 5 voxels, it is unlikely that IQ is driving the white matter differences between those 
with TRS and healthy controls. In addition, the remaining clusters showed no such relationship, 
therefore we suggest that the relationship between IQ, treatment resistance and microstructural 
measures of white matter is weak at best. 
This study benefits from a well characterised cohort of participants, well matched for clinical and 
demographic variables including gender, age, duration of illness, age at onset, duration of untreated 
psychosis and premorbid IQ. Participants taking clozapine had well-established TRS and patient 
groups were stabilized on their current treatment. Inclusion of patients with mild symptoms 
provides us with confidence that the differences in FA observed in those with TRS are unlikely to be 
the result of more severe active symptoms in this cohort. Correlation analysis with total PANSS 
scores supports this theory. 
Participants in the current study were responding well to treatment, with PANSS scores (mean total 
score 59.5-61.2) corresponding to mild symptom severity (Leucht et al., 2005). The decision to 
recruit well-responding participants was based on the desire to minimise interference from current 
symptoms on white matter measures but also to ensure that those in the FLR and TRS groups were 
truly responsive to first-line and clozapine monotherapy, respectively.  
This study has several limitations. Recent work has shown that the use of different head coils 
(namely 8- and 32-channel coils) can introduce positive bias when analysing white matter 
microstructure (Panman et al., 2019). However, the bias introduced by the use of 20- and 32-channel 
coils (as in the current study) is likely to be far less than that introduced by the use of 8- and 32-
channel coils. Although the use of both 20- and 32-channel head coils in the current study is a 
limitation, our decision not to exclude these participants based on head size was carefully 
considered. Recruitment of individuals with schizophrenia who meet the strict criteria set out in this 
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study is challenging and we believe the benefit of including more participants outweighs the 
potential bias introduced by the small number of participants with larger head size. In our study, 
individuals scanned with the 20-channel coil were well distributed among the treatment groups (two 
participants in the FLR group, one in the TRS group and two in the UTRS group) as well as in terms of 
their FA values (triangles in figures 4-6, S1 and S2). It is therefore unlikely that the use of this data 
introduced FA bias. Including the head coil as a regressor of no interest in the analysis resulted in a 
non-statistically significant effect of group on FA (p=.0548). As inclusion of the coil regressor resulted 
in only a small increase in p-value, it is unlikely to have contributed substantially to the effects 
observed in the main analysis. This is nonetheless an important consideration for future work. 
The sample size was comparable to other studies investigating white matter microstructure in 
treatment-resistant schizophrenia (Chen et al., 2018; Luck et al., 2011; Mitelman et al., 2006; Ochi et 
al., 2020), though would be considered relatively small compared with other neuroimaging studies. 
Studies involving larger cohorts of FLR, TRS and UTRS participants are required to confirm the results 
of our and other studies in this area (though (Reis Marques et al., 2014) found similar results of 
decreased FA in those with TRS in a study of 52 controls, 30 FLR and 33 people with TRS).  
The study’s cross–sectional design imparts a degree of uncertainty about the underlying cause of 
observed differences. However, these findings are in line with previous work highlighting differences 
between controls and non-responders to antipsychotic therapy, suggesting the effects are robust. 
Therefore, although our post hoc analyses did not survive corrections for multiple comparisons 
between groups, their concordance with previous work provides a strong foundation on which a 
theory attributing treatment resistance to white matter abnormalities can be built. 
In summary, these results suggest that microstructural white matter abnormalities in people with 
schizophrenia are more pronounced in those with TRS than those who respond well to first-line 
antipsychotics and those with UTRS and that these aberrations exist despite effective treatment with 
clozapine.  Future work is required to confirm the differences in FA values identified between those 
with TRS and UTRS in the current study and to evaluate whether differences between TRS and UTRS 
are present before initiation of clozapine. We hope these findings, in combination with the current 
literature, will encourage researchers to delineate between treatment-resistant and ultra-treatment 
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Figure 1. White matter maps showing lower fractional anisotropy (FA) in the treatment resistant 
schizophrenia (TRS) group compared to psychiatrically healthy controls (p < .05, FWE-corrected).  
Red-yellow voxels represent regions in which FA is significantly lower in the TRS group relative to 
healthy controls, overlaid on to the mean FA skeleton (green) and FMRIB58-FA image in standard 
20 
 
MNI-152 space (radiologic view with Z coordinates).  FWE = family-wise error; MNI = Montreal 
Neurological Institute. 
Figure 2. White matter maps showing lower fractional anisotropy (FA) in the treatment-resistant 
schizophrenia (TRS) group compared to the ultra-treatment-resistant schizophrenia (UTRS) group (p 
< .05, FWE-corrected).  Red-yellow voxels represent regions in which FA is significantly lower in the 
TRS group relative to UTRS, overlaid on to the mean FA skeleton (green) and FMRIB58-FA image in 
standard MNI-152 space (radiologic view with Z coordinates).  FWE = family-wise error; MNI = 
Montreal Neurological Institute. 
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Figure 3. Voxel clusters in which individuals with treatment-resistant schizophrenia (TRS) exhibited 
lower fractional anisotropy (FA) than psychiatrically healthy controls or those with ultra-treatment-
resistant schizophrenia (UTRS).  
Figure 4. Mean fractional anisotropy (FA) for clusters in which the group with treatment resistant 
schizophrenia (TRS) had significantly lower FA than healthy comparison subjects or those with ultra-
treatment-resistant schizophrenia (UTRS). Individual subjects’ mean FA values are represented by 
points, with group data represented by each box - lines through each box represent the group 
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median; the upper and lower "hinges" correspond to the first and third quartiles (the 25th and 75th 
percentiles). Data beyond the end of the whiskers are outliers (as specified by Tukey). 
Figure 5. Relationship between mean cluster fractional anisotropy (FA) and antipsychotic dose 
measured in chlorpromazine equivalents (CPZE) in those with schizophrenia. Pearson’s correlation 
(R) and uncorrected p values are presented for each cluster. 
Figure 6. Relationship between mean cluster fractional anisotropy (FA) and standardised 






Table 1. Demographic data (mean (SD) unless otherwise stated) of study participants by treatment group. *One participant in the TRS group did not 










(n=14) Test Statistic 
Sex (male/female) 17/3 14/4 14/4 11/3 Fisher’s Exact test (FET),  
p = .933 
Age at scan (years) 33.2 (8.4) 32.2 (7.9) 33.2 (8.2) 34.6 (7.0) F(3,66) = .31, p = .818 
Premorbid IQ (standardized scores) -0.838 (1.286) -0.781 (0.982) -0.955 (1.170) -0.885 (0.883) F(3,66) = .08, p = .971 
Age at onset (years) - 22.3 (5.5) 20.7 (4.5) 22.8 (6.4) F(2,47) = .64, p = .531 
Duration of illness (years) - 10.0 (7.9) 12.5 (6.7) 12.2 (4.8) F(2,47) = .73, p = .485 
Duration of untreated psychosis (months) - 12.5 (14.7) 11.1 (18.1) 22.5 (27.5) F(2,47) = 1.46, p = .242 
PANSS total score - 59.5 (11.0) 59.6 (14.1) 61.2 (10.9) F(2,47) = .09, p = .911 
PANSS positive  subscale score  - 13.4 (5.36) 11.9 (5.5) 12.6 (5.1) F(2,47) = .36, p = .703 
PANSS negative  subscale score  - 17.1 (5.75) 18.8 (6.8) 19.5 (7.6) F(2,47) = .57, p = .572 
PANSS general subscale score - 28.9 (6.01) 28.8 (6.2) 29.1 (4.4) F(2,47) = .01, p = .993 
Current prescribed antipsychotic - Olanzapine (n=8)  
Risperidone (n=6)  
Aripiprazole (n=3)  
Amisulpride (n=1)  
Clozapine (n=18) Clozapine + amisulpride (n = 4) 
Clozapine + aripiprazole (n = 4)  
Clozapine + risperidone (n = 2)   
Clozapine + quetiapine (n = 1)   
Aripiprazole + quetiapine (n = 2)  




Dose at time of scan (chlorpromazine 
equivalents) 
- 421.5 (191.6) 438.2 (229.3) 843.2 (377.4) F(2,47) = 12.03, p <.001 
UTRS vs FLR, p < .001 
UTRS vs TRS, p < .001 
Positive test for THC (n) 
 
0 3 1 3 FET, p = .096 
ASSIST total score* 26.4 (17.3) 50.2 (21.4) 38.0 (21.1) 53.8 (32.7) F(3,65) = 5.18, p = .003 
FLR vs Control, p = .013 
UTRS vs Control, p = .007 
Root mean squared motion (mm: median, 
IQR)  
     
From first volume 1.03 (1.87) 1.07 (0.41) 0.83 (0.66) 0.94 (1.06) Kruskal-Wallis (KW) chi 
squared test (3) = 2.94,    
p = .401  
From previous volume 0.23 (0.24) 0.32 (0.22) 0.29 (0.25) 0.25 (0.20) KW(3) = .170, p = .982 
Table 2.  Description of white matter clusters showing lower fractional anisotropy (FA) in those with treatment-resistant schizophrenia (TRS) compared with 
either psychiatrically healthy controls or those with ultra-treatment-resistant schizophrenia (UTRS). Regions are shown for the Juelich histological white 
matter labels and tractography atlases and are ordered according to greatest probability of the cluster residing in each region (averaged across all voxels in 
the cluster). Any region with low (<1%) probability of inclusion in a cluster has been excluded for ease of reporting only. 




Peak voxel (MNI-152 
coordinates, mm) 
 
JHU ICBM-DTI-81 White-Matter Labels 
 
JHU White-Matter Tractography Atlas 
 
x y z 
UTRS>TRS 
Cluster: 
       
25 
 
1 Superior longitudinal fasciculus (R) Superior longitudinal fasciculus 
(temporal part, R) 
Superior longitudinal fasciculus (R) 
 
395 0.03 50 104 103 
CON>TRS 
Cluster: 
       
7 Body of corpus callosum 
Superior longitudinal fasciculus (R) 
Splenium of corpus callosum 
Superior corona radiata (R) 
Posterior thalamic radiation (including optic 
radiation, R)  
Posterior corona radiata (R) 
 
 
Superior longitudinal fasciculus (R) 
Inferior fronto-occipital fasciculus (R) 
Forceps major 
Inferior longitudinal fasciculus (R) 
Corticospinal tract (R) 
Superior longitudinal fasciculus 
(temporal part, R)  
6150 .022 74 92 100 
6 Posterior thalamic radiation (include optic 
radiation) (L) 
Superior longitudinal fasciculus (L) 
Sagittal stratum (include inferior longitidinal 
fasciculus and inferior fronto-occipital 
fasciculus, L)  
 
Inferior longitudinal fasciculus (L) 
Inferior fronto-occipital fasciculus (L) 
Forceps major 
Superior longitudinal fasciculus (L) 
Superior longitudinal fasciculus 
(temporal part, L) 
4467 .029 124 67 75 
5 Cerebral peduncle (bilateral) 
Posterior limb of internal capsule (L) 
Anterior limb of internal capsule (L) 
Superior cerebellar peduncle (R) 
Fornix (cres) / Stria terminalis (L) 
Inferior cerebellar peduncle (R) 
Superior cerebellar peduncle (L) 
 
Anterior thalamic radiation (L) 
Corticospinal tract (bilateral) 
Anterior thalamic radiation (R) 
 
3747 .028 88 96 57 
4 Superior longitudinal fasciculus (L) 
Body of corpus callosum 
Superior corona radiata (L) 
Splenium of corpus callosum 
Posterior corona radiata (L) 
Anterior corona radiata (L) 
 
 
Superior longitudinal fasciculus (L) 
Superior longitudinal fasciculus 
(temporal part, L) 
 
3124 .025 110 96 110 
3  
 
Inferior longitudinal fasciculus (L) 120 .049 102 52 113 
26 
 
2 Superior longitudinal fasciculus (R) 
 
Superior longitudinal fasciculus (R) 
Superior longitudinal fasciculus 
(temporal part, R) 
116 .049 50 79 90 
1 External capsule (L) 
 
Inferior fronto-occipital fasciculus (L) 
Uncinate fasciculus (L) 
 
 
5 .050 118 142 70 
 
 
 
